Verrica Pharmaceuticals Inc. VRCA
Set alert
3.35 USD -0.07 -2.05%
At close · Oct 30
3.45 +0.10 +2.96%
After hours · Oct 30, 5:32 PM ET
3.25 Day range 3.47
3.28 52-week range 9.10
- YTD
- -59.69%
- 1 year
- -5.10%
- Open
- 3.42
- Prev close
- 3.42
- Mkt cap
- 57.55M
- Vol
- 33.79K
- Avg vol
- 69.47K
- EPS
- -1.75
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.25
- High
- 3.47
- Forward P/E
- -1.19
- Beta
- 1.46
- Short ratio
- 3.19
- Inst. own
- 15.80%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2024
- 50-d avg
- 1.12
- 200-d avg
- 4.58
- 1y target
- 6.33
2Y chart
Events in this range
- Nov 4, 2024Earnings: -0.49; estimate -0.37; surprise -32.43%
- Nov 5, 2024Downgrade: RBC Capital · Outperform → Sector Perform
- Nov 5, 2024Rating: Needham · — → Hold
- Nov 6, 2024Downgrade: HC Wainwright & Co. · Buy → Neutral
- Dec 20, 2024Rating: Needham · Hold → Hold
- Jul 25, 2025Split: 1 for 10
Signals (104)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 29, 2026 | 2 days ago |
| RSI: Oversold | Oct 19, 2026 | 1 week ago |
| RSI: Oversold | Oct 13, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 5, 2026 | 3 weeks ago |
| MACD: Buy Signal | Sep 30, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 11, 2026 | 1 month ago |
| SMA: Bearish | Aug 31, 2026 | 2 months ago |
| SMA: Bullish | Aug 28, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 25, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 12, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 11, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 10, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 5, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 14, 2026 | 3 months ago |
| SMA: Bearish | Jul 13, 2026 | 3 months ago |
| SMA: Bearish | Jul 10, 2026 | 3 months ago |
| SMA: Bullish | Jul 8, 2026 | 3 months ago |
| SMA: Bullish | Jul 2, 2026 | 4 months ago |
| SMA: Bearish | Jul 1, 2026 | 4 months ago |
| SMA: Bearish | Jun 30, 2026 | 4 months ago |
| SMA: Bullish | Jun 26, 2026 | 4 months ago |
| SMA: Bullish | Jun 25, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 25, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 18, 2026 | 4 months ago |
| SMA: Bearish | Jun 17, 2026 | 4 months ago |
| SMA: Bullish | Jun 16, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 16, 2026 | 4 months ago |
| SMA: Bearish | Jun 12, 2026 | 4 months ago |
| SMA: Bullish | Jun 11, 2026 | 4 months ago |
| SMA: Bearish | Jun 10, 2026 | 4 months ago |
| SMA: Bullish | Jun 4, 2026 | 4 months ago |
| SMA: Bearish | May 29, 2026 | 5 months ago |
| SMA: Bullish | May 22, 2026 | 5 months ago |
| SMA: Bearish | May 21, 2026 | 5 months ago |
| SMA: Bullish | May 20, 2026 | 5 months ago |
| SMA: Bearish | May 18, 2026 | 5 months ago |
| SMA: Bearish | May 18, 2026 | 5 months ago |
| MACD: Sell Signal | May 14, 2026 | 5 months ago |
| RSI: Overbought | May 6, 2026 | 5 months ago |
| MACD: Buy Signal | May 5, 2026 | 5 months ago |
| MACD: Sell Signal | May 4, 2026 | 6 months ago |
| SMA: Bullish | Apr 16, 2026 | 6 months ago |
| SMA: Bullish | Apr 15, 2026 | 6 months ago |
| SMA: Bearish | Apr 7, 2026 | 6 months ago |
| SMA: Bearish | Apr 7, 2026 | 6 months ago |
| SMA: Bullish | Apr 6, 2026 | 6 months ago |
| SMA: Bullish | Apr 6, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 1, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 23, 2026 | 7 months ago |
| SMA: Bearish | Mar 18, 2026 | 7 months ago |
| SMA: Bullish | Mar 11, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 6, 2026 | 7 months ago |
| SMA: Bearish | Feb 20, 2026 | 8 months ago |
| SMA: Bullish | Feb 18, 2026 | 8 months ago |
| RSI: Oversold | Feb 17, 2026 | 8 months ago |
| SMA: Bearish | Feb 11, 2026 | 8 months ago |
| RSI: Oversold | Feb 11, 2026 | 8 months ago |
| SMA: Bearish | Jan 28, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 17, 2025 | 10 months ago |
| RSI: Overbought | Dec 5, 2025 | 11 months ago |
| SMA: Bullish | Nov 26, 2025 | 11 months ago |
| RSI: Overbought | Nov 26, 2025 | 11 months ago |
| SMA: Bullish | Nov 21, 2025 | 11 months ago |
| SMA: Bearish | Nov 20, 2025 | 11 months ago |
| SMA: Bullish | Nov 19, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 10, 2025 | 11 months ago |
| RSI: Oversold | Nov 4, 2025 | 12 months ago |
| MACD: Sell Signal | Oct 24, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 29, 2025 | 1 year ago |
| RSI: Oversold | Sep 16, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 15, 2025 | 1 year ago |
| SMA: Bearish | Aug 13, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 12, 2025 | 1 year ago |
| SMA: Bullish | Aug 11, 2025 | 1 year ago |
| SMA: Bearish | Jul 29, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 22, 2025 | 1 year ago |
| RSI: Overbought | Jul 10, 2025 | 1 year ago |
| RSI: Overbought | Jul 7, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 3, 2025 | 1 year ago |
| SMA: Bullish | Jul 1, 2025 | 1 year ago |
| SMA: Bearish | Jun 27, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 18, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 9, 2025 | 1 year ago |
| SMA: Bullish | Jun 2, 2025 | 1 year ago |
| SMA: Bearish | May 30, 2025 | 1 year ago |
| MACD: Sell Signal | May 29, 2025 | 1 year ago |
| SMA: Bullish | May 13, 2025 | 1 year ago |
| MACD: Buy Signal | May 12, 2025 | 1 year ago |
| MACD: Sell Signal | May 7, 2025 | 1 year ago |
| SMA: Bearish | Apr 8, 2025 | 1 year ago |
| SMA: Bullish | Apr 7, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 7, 2025 | 1 year ago |
| RSI: Oversold | Apr 1, 2025 | 1 year ago |
| RSI: Oversold | Mar 27, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 21, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 18, 2025 | 1 year ago |
| SMA: Bearish | Feb 27, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 27, 2025 | 1 year ago |
| SMA: Bullish | Feb 26, 2025 | 1 year ago |
| SMA: Bearish | Feb 24, 2025 | 1 year ago |
| SMA: Bullish | Feb 14, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 6, 2025 | 1 year ago |
| RSI: Oversold | Dec 26, 2024 | 1 year ago |
| RSI: Oversold | Dec 16, 2024 | 1 year ago |
Key statistics
- Market cap
- 63.71M
- Enterprise value
- 55.81M
- Trailing P/E
- 0.00
- Forward P/E
- -1.19
- PEG ratio
- 0.00
- Price / sales
- 6.92
- Price / book
- 0.00
- EPS (TTM)
- -1.84
- Beta
- 1.46
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 9.21M
- Revenue growth
- 0.00%
- Free cash flow
- -31.81M
- Total cash
- 22.96M
- Total debt
- 47.11M
- Return on equity
- -2059.89%
- Shares outstanding
- 90.56M
- Short % of float
- 4.54%
- 50-day average
- 1.12
- 200-day average
- 4.58
Analyst view
Consensus: buy
Buy
Price target (mean) 6.33 +89.1% upside
Now 3.35
- Target (low)
- 2.00
- Target (mean)
- 6.33
- Target (high)
- 12.00
Ratings (0m) 6 2 buy · 4 hold · 0 sell
- Strong buy0
- Buy2
- Hold4
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate -0.284.
Financials — quick view
VRCA Revenue — quarterly 5.86M
VRCA Net income — quarterly -13.15M
VRCA EPS — quarterly -0.62
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2024 | Sep 1, 2024 | -0.37 | -0.49 | -0.12 | -32.43% |
| Aug 14, 2024 | Jun 1, 2024 | -0.43 | -0.31 | +0.12 | +27.91% |
| Aug 14, 2024 | Jun 1, 2024 | -0.43 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | -0.54 | -0.38 | +0.16 | +29.63% |
| May 13, 2024 | Mar 1, 2024 | -0.54 | — | — | — |
| Feb 29, 2024 | Dec 1, 2023 | -0.47 | -0.48 | -0.01 | -2.13% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 20, 2024 | Needham | reit | Hold | Hold |
| Nov 6, 2024 | HC Wainwright & Co. | down | Buy | Neutral |
| Nov 5, 2024 | Needham | reit | — | Hold |
| Nov 5, 2024 | RBC Capital | down | Outperform | Sector Perform |
| Oct 21, 2024 | TD Cowen | main | Buy | Buy |
| Oct 4, 2024 | RBC Capital | main | Outperform | Outperform |
About Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- verrica.com
News
- Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit Facility
- Verrica Pharmaceuticals Q2 2026 Earnings Call Transcript
- Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Stock Has Average Price Target of $12.67 According to Brokerages
- Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences
- Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences
- Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
- Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027
- Verrica Pharmaceuticals Q2 Earnings Call Highlights
- Verrica Pharmaceuticals Inc. (VRCA) Q2 2026 Earnings Call Transcript
- Verrica Pharmaceuticals Q2 Adj. EPS $(0.48) Misses $(0.38) Estimate, Sales $5.862M Beat $5.733M Estimate
Your note
Sign in to keep a note on VRCA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BONACCORSO JOE | Officer | Sale | Aug 26, 2024 | 73,114 |
| GOLDENBERG GARY | Officer | Sale | Aug 26, 2024 | 94,261 |
| HAYES CHRISTOPHER G | Officer | Sale | Aug 26, 2024 | 105,773 |
| KIRBY JOHN J. | Chief Financial Officer | Stock Award(Grant) | Nov 5, 2024 | 54,267 |
| KOHLER TERRY | Chief Financial Officer | Sale | Aug 26, 2024 | 44,697 |
| MANNING PAUL B. | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Gift | Nov 25, 2024 | 38,060,800 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Perceptive Advisors Llc | 15.57% | 7,099,182 | 4.99M | Sep 29, 2024 |
| Vanguard Group Inc | 2.82% | 1,286,600 | 905.12K | Sep 29, 2024 |
| Blackrock Inc. | 2.38% | 1,085,439 | 763.61K | Sep 29, 2024 |
| FMR, LLC | 1.39% | 634,310 | 446.24K | Sep 29, 2024 |
| State Street Corporation | 1.12% | 512,821 | 360.77K | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.00% | 455,480 | 320.43K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.79% | 815,893 | 573.98K | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.19% | 540,966 | 380.57K | Oct 30, 2024 |
| Fidelity Select Portfolios - Biotechnology | 1.14% | 517,629 | 364.15K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.63% | 289,249 | 203.49K | Sep 29, 2024 |
| Simplify Exchange Traded Fds-Simplify Propel Opportunities ETF | 0.44% | 200,000 | 140.70K | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.43% | 196,507 | 138.24K | Aug 30, 2024 |